Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Immix stock

Learn how to easily invest in Immix stock.

Immix Biopharma Inc is a biotechnology business based in the US. Immix shares (IMMX) are listed on the NASDAQ and all prices are listed in US Dollars. Immix employs 2 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Immix

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IMMX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Immix stock price (NASDAQ: IMMX)

Use our graph to track the performance of IMMX stocks over time.

Immix shares at a glance

Information last updated 2022-07-02.
Latest market close$2.60
52-week range$1.25 - $7.90
50-day moving average $1.97
200-day moving average $2.88
Wall St. target priceN/A
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-3.93

Buy Immix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Immix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immix price performance over time

Historical closes compared with the close of $2.6 from 2022-07-01

1 week (2022-06-29) 3.17%
1 month (2022-06-06) 2.36%
3 months (2022-04-06) 28.08%
6 months (2022-01-06) -52.64%
1 year (2021-07-02) N/A
2 years (2020-07-02) N/A
3 years (2019-07-02) N/A
5 years (2017-07-02) N/A

Immix financials

Gross profit TTM $0
Return on assets TTM -15.46%
Return on equity TTM -331.05%
Profit margin 0%
Book value $1.42
Market capitalisation $36.1 million

TTM: trailing 12 months

Immix share dividends

We're not expecting Immix to pay a dividend over the next 12 months.

You may also wish to consider:

Immix overview

Immix Biopharma, Inc. , a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California. .

Frequently asked questions

What percentage of Immix is owned by insiders or institutions?
Currently 62.654% of Immix shares are held by insiders and 1.618% by institutions.
How many people work for Immix?
Latest data suggests 2 work at Immix.
When does the fiscal year end for Immix?
Immix's fiscal year ends in December.
Where is Immix based?
Immix's address is: 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
What is Immix's ISIN number?
Immix's international securities identification number is: US45258H1068

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site